LENSAR® Reports Third Quarter 2025 Results and Provides Business Update

18 ALLY Robotic Cataract Laser Systems ® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2025 and provided an update on key operational initiatives.

GlobeNewsWire • Nov 6, 2025

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”).

GlobeNewsWire • Sep 2, 2025

Lensar (LNSR) Q2 Revenue Rises 10%

Lensar (LNSR) Q2 Revenue Rises 10%

The Motley Fool • Aug 7, 2025

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025

GlobeNewsWire • Aug 7, 2025

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.

Business Wire • Jun 3, 2025

LENSAR Reports First Quarter 2025 Results and Provides Business Update

14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025

GlobeNewsWire • May 8, 2025

ALC Stock Rises Following the Merger Agreement With LENSAR

Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.

Zacks Investment Research • Mar 25, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of LENSAR, Inc. - LNSR

NEW YORK , March 24, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating LENSAR, Inc. (NASDAQ: LNSR ), relating to the proposed merger with Alcon.

PRNewsWire • Mar 24, 2025

Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating LENSAR (NASDAQ: LNSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, LENSAR shareholders will receive only $14.00 per share in cash (an aggregate implied value of approximately $3.

Business Wire • Mar 24, 2025

LNSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LENSAR, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LENSAR, Inc. (NASDAQ: LNSR) to Alcon for $14.00 per share in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, is fair to LENSAR shareholders. Halper Sadeh encourages LENSAR shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper.

Business Wire • Mar 24, 2025